<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03268811</url>
  </required_header>
  <id_info>
    <org_study_id>SHP633-305</org_study_id>
    <nct_id>NCT03268811</nct_id>
  </id_info>
  <brief_title>A Study in Japanese Children With Short Bowel Syndrome Who Completed SHP633-302</brief_title>
  <official_title>A Prospective, Open-label, Long-term Safety and Efficacy Study of Teduglutide in Japanese Pediatric Subjects With Short Bowel Syndrome Who Completed SHP633-302</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shire</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shire</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this clinical study is to evaluate the long-term safety and tolerability of
      teduglutide treatment in Japanese pediatric participants with short bowel syndrome (SBS) who
      completed Study SHP633-302 (NCT02980666).
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">August 23, 2017</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Adverse Events (AE)</measure>
    <time_frame>Baseline to each study visit for approximately 3 years</time_frame>
    <description>An AE is any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Clinically Significant Abnormalities in Vital Signs Reported as an Adverse Event</measure>
    <time_frame>Baseline to each study visit for approximately 3 years</time_frame>
    <description>Vital signs include systolic and diastolic blood pressure, heart rate and body temperature.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Clinically Significant Laboratory Safety Data Reported as an Adverse Event</measure>
    <time_frame>Baseline to each study visit for approximately 3 years</time_frame>
    <description>Laboratory safety data includes biochemistry, hematology and urinalysis.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Significant Change in Urine Output Reported as an Adverse Event</measure>
    <time_frame>Baseline to each study visit for approximately 3 years</time_frame>
    <description>Urine output will be recorded in the output diary over a 48-hour period of parenteral support (PS) stability.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Significant Change in Stool Output Reported as an Adverse Event</measure>
    <time_frame>Baseline to each study visit for approximately 3 years</time_frame>
    <description>Stool output will be recorded in the output diary over a 48-hour period of PS stability.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Positive Specific or Neutralizing Antibodies to Teduglutide</measure>
    <time_frame>Baseline to each study visit for approximately 3 years</time_frame>
    <description>Blood samples will be drawn for the analysis of positive/specific antibodies to teduglutide.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With a Positive Fecal Occult Blood Testing</measure>
    <time_frame>Baseline to each study visit for approximately 3 years</time_frame>
    <description>Gastrointestinal-specific assessment will be analysed by fecal occult blood testing. Participants with newly positive fecal occult blood testing results at the pre-treatment visit for which a readily detectable cause cannot be identified (example: anal fissure ) will undergo a colonoscopy prior to receiving teduglutide.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Colonoscopy/Sigmoidoscopy Results</measure>
    <time_frame>Baseline to each study visit for approximately 3 years</time_frame>
    <description>Participants who have received the equivalent of 2 treatment cycles (48 weeks of investigational product exposure) will undergo colonoscopy/sigmoidoscopy.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Z-Score Body Weight</measure>
    <time_frame>Baseline to each study visit for approximately 3 years</time_frame>
    <description>The Z-score indicates the number of standard deviations away from the mean.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Z-Score Height</measure>
    <time_frame>Baseline to each study visit for approximately 3 years</time_frame>
    <description>The Z-score indicates the number of standard deviations away from the mean.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Z-Score Head Circumference</measure>
    <time_frame>Baseline to each study visit for approximately 3 years</time_frame>
    <description>The Z-score indicates the number of standard deviations away from the mean.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Z-Score Body Mass Index (BMI)</measure>
    <time_frame>Baseline to each study visit for approximately 3 years</time_frame>
    <description>The Z-score indicates the number of standard deviations away from the mean.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants who Demonstrate at least 20 Percent (%) Reduction From Baseline in Parenteral Support (PS) Volume</measure>
    <time_frame>Baseline to each study visit for approximately 3 years</time_frame>
    <description>PS (parenteral nutrition or intravenous fluids) will be considered for managing nutritional support in terms of volume and calories during the treatment period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Change From Baseline in Parenteral Support (PS) Volume</measure>
    <time_frame>Baseline to each study visit for approximately 3 years</time_frame>
    <description>PS (parenteral nutrition or intravenous fluids) will be considered for managing nutritional support in terms of volume and calories during the treatment period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relative Change From Baseline in Parenteral Support (PS) Volume</measure>
    <time_frame>Baseline to each study visit for approximately 3 years</time_frame>
    <description>PS (parenteral nutrition or intravenous fluids) will be considered for managing nutritional support in terms of volume and calories during the treatment period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants who Completely Wean off Parenteral Support (PS)</measure>
    <time_frame>Baseline to each study visit for approximately 3 years</time_frame>
    <description>PS (parenteral nutrition or intravenous fluids) will be considered for managing nutritional support in terms of volume and calories during the treatment period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Days per Week of Parenteral Support (PS)</measure>
    <time_frame>Baseline to each study visit for approximately 3 years</time_frame>
    <description>PS (parenteral nutrition or intravenous fluids) will be considered for managing nutritional support in terms of volume and calories during the treatment period.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">7</enrollment>
  <condition>Short Bowel Syndrome</condition>
  <arm_group>
    <arm_group_label>Teduglutide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive teduglutide 0.05 milligram per kilogram (mg/kg) subcutaneous (SC) injection once daily into 1 of the 4 quadrants of the abdomen or either thigh or arm for 24-week intervals. If a participant deteriorates during a follow-up period, the participant may be evaluated immediately for additional teduglutide treatment (24-week interval) until teduglutide is commercially available for each participant, the participant's participation in this study is discontinued, or the study is discontinued.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Teduglutide</intervention_name>
    <description>Teduglutide 0.05 mg/kg SC injection will be administered once daily into 1 of the 4 quadrants of the abdomen or either thigh or arm.</description>
    <arm_group_label>Teduglutide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Syringe</intervention_name>
    <description>Teduglutide will be administered using a syringe. Syringe is approved for use in Japan by pharmaceuticals and medical devices agency (PMDA).</description>
    <arm_group_label>Teduglutide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Needle</intervention_name>
    <description>Teduglutide will be administered using needle. Needle is approved for use in Japan by PMDA.</description>
    <arm_group_label>Teduglutide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Vial Adapter for Device</intervention_name>
    <description>Vial adapter for device is approved for use in Japan by PMDA.</description>
    <arm_group_label>Teduglutide</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Informed consent by a parent or guardian prior to any study-related procedures.

          -  When applicable, informed assent (as deemed appropriate by the Institutional Review
             Board [IRB]) by the participant prior to any study-related procedures.

          -  Participant completed Study SHP633-302 (NCT02980666).

          -  Participant (and/or parent/guardian) understands and is willing and able to fully
             adhere to study requirements as defined in this protocol.

        Exclusion Criteria:

        There are no exclusion criteria for this study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Shire</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kyushu University Hospital</name>
      <address>
        <city>Fukuoka-shi</city>
        <state>Fukuoka-ken</state>
        <zip>812-8582</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tsukuba University Hospital</name>
      <address>
        <city>Tsukuba</city>
        <state>Ibaraki-Ken</state>
        <zip>305-8576</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kagoshima University Hospital</name>
      <address>
        <city>Kagoshima</city>
        <state>Kagoshima-Ken</state>
        <zip>890-8520</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tohoku University Hospital</name>
      <address>
        <city>Sendai-shi</city>
        <state>Miyagi-Ken</state>
        <zip>980-8574</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Showa University</name>
      <address>
        <city>Shinagawa-ku</city>
        <state>Tokyo-To</state>
        <zip>142-8555</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>August 10, 2017</study_first_submitted>
  <study_first_submitted_qc>August 29, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 31, 2017</study_first_posted>
  <last_update_submitted>July 1, 2020</last_update_submitted>
  <last_update_submitted_qc>July 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Short Bowel Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Teduglutide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>De-identified individual participant data from this particular study will not be shared as there is a reasonable likelihood that individual patients could be re-identified (due to the limited number of study participants/study sites, â€¦).</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

